Effect of angiotensin converting enzyme inhibitor or beta-blocker use on the benefit of fixed-dose combined isosorbide dinitrate/hydralazine in the African-American heart failure trial

被引：0
|
作者：
Ghali, Jalal K.
Taylor, Anne L.
Tam, S. William
Sabolinski, Michael L.
Worcel, Manuel
Cohn, Jay N.
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] Univ Minnesota, Minneapolis, MN USA
[3] Nitromed Inc, Clin & Regulatory, Lexington, MA USA
来源：
JOURNAL OF CARDIAC FAILURE | 2006年 / 12卷 / 06期
关键词：
D O I：
10.1016/j.cardfail.2006.06.273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
259
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 38 条
  • [31] Beneficial effects of isosorbide dinitrate-hydralazine on survival in heart failure is independent of its blood pressure lowering effect - Results from African American heart failure trial
    Anand, IS
    Tam, SW
    Archambault, WT
    Olukotun, AY
    Adams, KF
    Worcel, M
    Sabolinski, ML
    Taylor, AL
    Cohn, JN
    CIRCULATION, 2005, 112 (17) : U704 - U704
  • [32] Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients
    Shah, Priyank
    Owens, Jack
    Franklin, James
    Jani, Yash
    Kumar, Ashish
    Doshi, Rajkumar
    JOURNAL OF HYPERTENSION, 2020, 38 (12) : 2537 - 2541
  • [33] Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID2): an evidence-based mnemonic for the treatment of systolic heart failure
    Chia, N.
    Fulcher, J.
    Keech, A.
    INTERNAL MEDICINE JOURNAL, 2016, 46 (06) : 653 - 663
  • [34] The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor nitrate therapy in heart failure
    Levine, TB
    Levine, AB
    Keteyian, SJ
    Narins, B
    CLINICAL CARDIOLOGY, 1998, 21 (12) : 899 - 904
  • [35] "Triple Therapy" of Heart Failure With Angiotensin-Converting Enzyme Inhibitor, Beta-Blocker, and Aldosterone Antagonist May Triple Survival Time Shouldn't We Tell Patients?
    Cole, Graham D.
    Patel, Sheetal J.
    Zaman, Nabeela
    Barron, Anthony J.
    Raphael, Claire E.
    Mayet, Jamil
    Francis, Darrel P.
    JACC-HEART FAILURE, 2014, 2 (05) : 545 - 548
  • [36] Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction:: findings of the PRIAMHO-II registry
    Aros, Fernando
    Loma-Osorio, Angel
    Vila, Joan
    Lopez-Bescos, Lorenzo
    Cunat, Jose
    Rodriguez, Emilio
    Jose, Jose M. San
    Heras, Magda
    Marrugat, Jaume
    REVISTA ESPANOLA DE CARDIOLOGIA, 2006, 59 (04): : 313 - 320
  • [37] Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction
    Kane, Jesse A.
    Kim, Joseph K.
    Haidry, Syed Abbas
    Salciccioli, Louis
    Lazar, Jason
    CARDIOLOGY, 2017, 137 (02) : 121 - 125
  • [38] New Scoring System Using Cardiopulmonary Exercise Parameters Can Predict Prognosis in Heart Failure Patients Receiving Guideline-Directed Optimal Medical Therapy Including Beta-Blocker, Angiotensin Converting Enzyme Inhibitor, and Aidosterone Antagosnit
    Imamura, T.
    Kinugawa, K.
    Inaba, T.
    Maki, H.
    Hatano, M.
    Kinoshita, O.
    Nawata, K.
    Ono, M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S177 - S178
1234